Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.
Jun 22, 2021
Modus Therapeutics Holding AB receives preliminary approval for listing and publishes prospectus
Jun 11, 2021
Modus Therapeutics and Imperial College London Sign Clinical Collaboration Targeting Severe Malaria
May 6, 2021
Modus Therapeutics publishes interim report for Q1